Hims Reports $33M Loss Amid Shift to GLP-1 Weight Loss Drugs
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Xeber.world
telehealth
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Hims Reports Sales Shortfall Amid Rising Telehealth Competition
Hims & Hers, a leading telehealth company, reported a sales miss as competition in the digital health space intensifies. The company's financial resul...
Supreme Court Blocks New Abortion Pill Restrictions in Temporary Stay Extension
The U.S. Supreme Court extended a temporary freeze on new restrictions for the abortion pill mifepristone, allowing mail-order prescriptions to contin...
Federal Court Halts Mailing of Mifepristone, Sparking Legal and Healthcare Debate
A federal court has blocked the mailing of mifepristone, a key abortion medication, raising concerns over access to reproductive healthcare. The decis...
How Kelonia Therapeutics’ $3.25B buyout reveals CAR-T’s high-stakes turnaround and drugmakers’ new strategies
Kelonia Therapeutics, a CAR-T biotech on the brink of collapse three times, was acquired by Eli Lilly for $3.25 billion. The deal highlights the secto...
Sanofi's Research Priorities Under Scrutiny as New CEO Belén Garijo Takes Charge
Sanofi's research priorities are under review as new CEO Belén Garijo begins her tenure. The company's recent focus on immunology has yielded lacklust...
Pharmalittle: Rising Concerns Over Telehealth Fees and Drug Approval Controversies
Health policy experts and legislators are raising concerns over high fees paid by pharmaceutical companies to telehealth providers, potentially violat...
RFK Jr.'s Peptide Push Could Spark $180B Wellness Boom—Here's Who Wins
Robert F. Kennedy Jr.'s campaign to ease federal restrictions on peptides could trigger a massive wellness trend, benefiting telehealth firms, compoun...
How Pharma Coupons and Telehealth Are Boosting Addyi Prescriptions for Low Libido
Addyi, the controversial 'little pink pill' for low libido in premenopausal women, expanded its FDA approval in December to include all women under 65...
New York Times Updates Article on AI Startup Medvi After Reader Criticism Over Omissions
The New York Times has revised a profile of AI startup Medvi after readers highlighted missing details about FDA warnings, legal actions, and deceptiv...